On the 26th of May Hamish Coleman-Ross and I hosted the NewstalkZB show “The Nutters Club.”
We talked with Dr Peter Surman, Chief Scientific Officer at Douglas Pharmaceuticals based in West Auckland, about a new ketamine-based drug they are developing which in early trials is showing signs of successfully supporting people experiencing serious, treatment resistant depression. They are hopeful that this drug will become a viable alternative to ECT, and will eventually be widely available in Aotearoa New Zealand and overseas.
With thanks to NZ on Air.
To listen to the audio of the show, it’s in two parts, click the links below…